Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

Roche announced pivotal phase III Krascendo 1 trial results showing its investigational drug divarasib significantly outperformed first-generation KRAS G12C inhibitors (sotorasib and adagrasib) in previously treated KRAS G12C-mutated non-small cell lung cancer. Divarasib achieved a median overall survival of approximately 18 months versus 12 months for competitors, reducing death risk by 44% and disease progression risk by 42%, with a manageable safety profile.